Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis

Abstract

Our data support the novel concept of glycolytic reprogramming in the pathogenesis of lung fibrosis and provide proof-of-concept that targeting this pathway may be efficacious in treating fibrotic disorders, such as idiopathic pulmonary fibrosis.